Authors

What Clinical Trials Can Learn from the Gig Economy About Payments

Outdated payment methods like prepaid cards and checks create administrative burden and retention friction, but modern flexible payment platforms with multiple payout options and global reach can improve participant experience without adding compliance complexity.

From Study End to Long-Term Insight: Choosing the Right Vaccine Follow-up Strategy

Vaccine developers can reduce participant burden and extend follow-up timelines by strategically combining traditional site visits with real-world data collection, but the choice depends on follow-up duration, data requirements, and the patient population being studied.

The Transformative Power of Data Analytics in Clinical Trials

Leveraging and benchmarking insights to boost efficiency and optimization.

5 Strategies for Bridging the Sponsor-Site Tech Divide

Results from survey of 100 site personnel suggest a disconnect is present between these stakeholders.

Empowering the Workforce of the Future: The Trends and Training That Will Drive the Future of Drug Development

A new global report finds that clinical research teams are making progress but still lack the skills and tools needed to keep pace with growing trial complexity and emerging technologies.

Applied AI and Advanced Automation in Clinical Trials

Use cases spotlight the growing potential of generative AI in the CRO space.

Beyond Eligibility: Making Trust and Behavioral Readiness Actionable in Clinical Trial Recruitment

Eligibility criteria alone rarely predict enrollment, which depends more on trust, hope, and fear, requiring relationship-based community engagement paired with behavioral readiness assessments rather than transactional outreach.

After the Trial is too Late: The Case for More Active Use of Patient-Reported Outcomes in Oncology Studies

Advancing toward more meaningful use of PRO data by making it systematic, transparent, and built into trial design.

Clinical Trial Monitoring: Should Randomization Be Included?

While randomization is required by regulatory bodies, it is up to the sponsor on how to conduct it.

Foundational Content Consolidation for Regulatory-Ready Digital End Points: Insights From Public-Private Partnerships

Public-private collaboration and structured evidence consolidation are emerging as critical enablers of regulatory-ready digital end points, helping standardize terminology, reduce duplication, and accelerate the integration of digital health technologies into clinical research and decision-making.

Built-In, Not Bolted On: Why Clinical Data Security Has to Be a Design Principle

Clinical data security built into system architecture from the foundation, rather than layered on afterward, reduces regulatory risk and actually accelerates research by removing manual compliance burden and improving team confidence in data integrity.

The Challenges of Buying Blind: Why Providing the Clinical Outcome Assessment Measure Prior to License Execution Would Significantly Benefit Clinical Trial Set-Up

Persistent delays and inefficiencies in COA licensing and translation stem from limited pre-license access and fragmented processes, making a strong case for providing outcome assessment measures earlier to reduce risk and accelerate trial start-up.

A Signal Isn’t Resolved Until It Stays Closed—RBQM Lessons

Analysis of more than 880 clinical trials shows that while statistical data monitoring and key risk indicator signals close on similar timelines, durability—not speed—is the defining differentiator in effective, risk-based quality management.

2026 DIA Global Annual Meeting: Stacy Hurt of Parexel on Federated AI, the Patient Voice, and Accountability for Patient Needs

In this video interview from the 2026 DIA Global Annual Meeting, Stacy Hurt, chief patient officer at Parexel, explains how federated AI is expanding what's possible in oncology research, why the patient voice gets lost earliest in development, and why someone in every organization needs to explicitly own patient needs from the very beginning.

Harnessing Unstructured Data and Hospital Interoperability

The potential of next-generation platforms in transforming patient recruitment.

Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond

Digital Measures of Health: What’s in it for Patients?

Exploring the different stages in the development of a digital measure, and the activities and steps key to achieving meaningful impact for patients.

What Real-World Data Shows About Current Cancer Care

Webinar Date/Time: Thu, May 7, 2026 1:00 PM EDT

Front-Loading Drug Development: Q&A with Jenna DiRito, PhD, Revalia Bio

In this Q&A, Jenna DiRito, PhD, COO and co-founder of Revalia Bio, discusses how earlier, human-relevant data is reshaping go/no-go decision-making in drug development and what a truly front-loaded workflow looks like in practice.

Clinical Trials as a Competitive Edge: Strategic Considerations

Navigating a complex drug development landscape, sponsors must rethink their approach to risk in study design and execution.

The Future is Now: Four Ways AI and Other Tech Advances are Enhancing Clinical Trials

Emerging applications of AI/ML, automation, and digitization are helping sponsors cut clinical trial start-up times to as little as four weeks, reduce data errors, and enhance patient engagement—demonstrating how tech-enabled processes are reshaping trial efficiency and experience across the study lifecycle.

When AI Learns to Speak Every Language: An eCOA Migration Study

New data show that applying AI to the migration of translated COAs into eCOA platforms can meaningfully reduce errors, accelerate localization workflows, and support broader global patient participation—while still relying on human reviewers to ensure linguistic precision and clinical integrity.

Evolving Toward Empowerment: How We Are Deepening Relationships With Patients

Multilayered strategies such as working with patient advocacy organizations and leveraging technology can help industry better partner with patients.

Harnessing Technology and Adopting Unified Approaches to Optimize Pharmacovigilance Activities

How digital intake solutions driven by technological advancements can help overcome the challenges of operating across different regulatory markets.

Why Real-World Evidence Can No Longer Wait Until After Approval

Real-world evidence is shifting from a post-market footnote to a concurrent validation layer running alongside trial data, requiring organizations to build unified data environments that integrate EHRs, claims, and patient-reported outcomes on an ongoing basis rather than retrospectively.

Critical Questions to Ask Your IRB

Find out if you’re working with the right IRB.

Focusing on Site Needs and Challenges: Quick Tips for Sponsors/CROs

Gain insight into how listening to site feedback and prioritizing engagement, training, and local patient understanding can drive smoother startups and stronger study outcomes.

Rethinking Oncology Trials With a Statistical Methodology That Puts Patients First

New statistical frameworks such as net treatment benefit offer a multidimensional approach to evaluating efficacy, safety, and patient-centered outcomes in oncology trials.

Scaling eSource-Enabled Clinical Trials: Hospital Perspectives

The challenges, opportunities, and strategic outlook for oncology research centers.